Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1997-7-15
|
pubmed:abstractText |
The effect of the administration route, dose, and sampling time on the total urinary excretion of four major benzo[a]pyrene (BaP) metabolites, 3-hydroxyBaP (3-OHBaP), 9-hydroxyBaP 9-hydroxyBaP (9-OHBaP), trans-4,5-dihydrodiolBaP (4,5-diolBaP), and trans-9,10-dihydrodiolBaP (9,10-diolBaP), was studied in male Sprague-Dawley rats exposed to a single intravenous, oral, and cutaneous dose of 2, 6, 20, and 60 mumol BaP/kg. Urine samples were collected at 24-h intervals following treatment. Over the 0-72 h period and for a given dose, amounts of BaP metabolites were 3-OHBaP > 4,5-diolBaP > > 9-OHBaP following intravenous and oral dosing, and 3-OHBaP > > 9-OHBaP > or = 4,5-diolBaP after cutaneous treatment. 9,10-diolBaP was barely detected. On the other hand, amounts of 3-OHBaP and 4,5-diolBaP excreted in urine over the 0-72 h period and for a given dose appeared in the following order: intravenous approximately oral > or = cutaneous. Amounts of 9-OHBaP excreted varied as follows: oral > or = cutaneous > intravenous. For all routes of administration, excretion of 4,5-diolBaP was almost complete over the 0-24 h period in contrast with 3-OHBaP and 9-OHBaP. Peak excretion of 3-OHBaP and 9-OHBaP was reached in the 0-24 h period following intravenous and oral treatment and in the 24-48 h period following cutaneous application. Overall, for a given administration route and dose, there were variations in the time profiles between metabolites. In general, there was nonetheless a good correlation between the BaP dose and urinary excretion of 3-OHBaP, 9-OHBaP, and 4,5-diolBaP. Furthermore, total urinary excretion of a specific metabolite, its time profile, and the relative proportion of the metabolites studied depended on the administration route. Data also suggest that a measure of the concentration ratio of the different metabolites could reflect the time and main route of exposure.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3-hydroxybenzo(a)pyrene,
http://linkedlifedata.com/resource/pubmed/chemical/4,5-dihydroxy-4,5-dihydrobenzo(a)pyr...,
http://linkedlifedata.com/resource/pubmed/chemical/9-hydroxybenzo(a)pyrene,
http://linkedlifedata.com/resource/pubmed/chemical/Benzo(a)pyrene,
http://linkedlifedata.com/resource/pubmed/chemical/Benzopyrenes,
http://linkedlifedata.com/resource/pubmed/chemical/Dihydroxydihydrobenzopyrenes,
http://linkedlifedata.com/resource/pubmed/chemical/Environmental Pollutants
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0008-4212
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
75
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
185-92
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9164700-Administration, Cutaneous,
pubmed-meshheading:9164700-Administration, Oral,
pubmed-meshheading:9164700-Animals,
pubmed-meshheading:9164700-Benzo(a)pyrene,
pubmed-meshheading:9164700-Benzopyrenes,
pubmed-meshheading:9164700-Dihydroxydihydrobenzopyrenes,
pubmed-meshheading:9164700-Environmental Pollutants,
pubmed-meshheading:9164700-Injections, Intravenous,
pubmed-meshheading:9164700-Male,
pubmed-meshheading:9164700-Rats,
pubmed-meshheading:9164700-Rats, Sprague-Dawley
|
pubmed:year |
1997
|
pubmed:articleTitle |
Urinary excretion of benzo[a]pyrene metabolites following intravenous, oral, and cutaneous benzo[a]pyrene administration.
|
pubmed:affiliation |
Départment de médecine du travail et d'hygiène du milieu, Université de Montréal, QC, Canada.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|